More News! 30 Sep 2018 Trouble in the Soil Bed: Sex Toys for Plants We live in a society obsessed with sex. Yet many of us forget that other living beings can have their own issues and needs in the reproductive area. A group of artists and designers from Slovenia got together to create fictional sex toys for the specific problems of plants. A dildo for carnivorous plants and […] September 30, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Sep 2018 Roche Acquires UK Cancer Immunotherapy Biotech in Deal Worth up to €655M Tusk Therapeutics has been acquired by Swiss pharma giant Roche, which aims to develop one of its lead immunological cancer treatments. Roche has given Tusk’s shareholders €70M upfront, with up to an additional €585M planned if Tusk achieves certain milestones. Roche seems particularly interested in one of Tusk’s lead programs, an antibody that reduces the […] September 28, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 28 Sep 2018 This Spanish Biotech Helps Personalize Post-Kidney Transplant Care We arrive in the city of Madrid this week to showcase Biohope, which is developing a technique to combat kidney transplant rejection by tailoring immunosuppressant treatments to individual patients. Mission: Founded in 2015, Biohope is developing a commercial lab kit, called Immunobiogram, that predicts the most effective immunosuppressant drugs for kidney transplant patients. Around […] September 28, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Sep 2018 Update: Series A Boost Pushes Belgian Microbiome Spin-Off Forward Update (27/09/2018): New investment from Dutch venture capital fund Innovation Industries brings A-Mansia’s Series A round up to €18M. The company’s first human study of the effects of A. muciniphila in volunteers is currently underway at the University of Louvain. Published on 27/04/2018 A-Mansia Biotech has raised €13M in Series A financing led by Seventure Partners. The […] September 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Expert Advice 27 Sep 2018 How to Build an Outstanding Personal Brand in the Biopharma Industry “Your brand is what people say about you when you’re not in the room.” – Jeff Bezos Your personal brand is essentially your professional reputation, publicised. In this crazy century, every individual has become the writer, editor, and creative director of their own publication. The internet has made the wisdom of company branding […] September 27, 2018 - 9 minutesmins - By James Mathison Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2018 Spanish Biotech Raises €21.3M To Advance Rare Disease Pipeline Rare genetic diseases in the central nervous system may be less of a headache in future, as Barcelona-based biotech Minoryx has raised €21.3M in series B fundraising to test its lead drug candidate against other rare neurological conditions. According to Philippe Monteyne, partner at investor Fund+, “it is the largest investment in biotech in Spain […] September 26, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 26 Sep 2018 Fish Oils Finally Reel in Positive Results for Cardiovascular Disease Purified fish oil can reduce patients’ risks for adverse cardiovascular events by 25%, according to US-Irish Biotech Amarin’s Phase III trial results. The treatment, called Vascepa, significantly reduced the risk of strokes, heart attacks, and death. It also had a good safety profile in the over 8,000 enrolled patients, who were already taking statins. These […] September 26, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 25 Sep 2018 24-Hour Blood Pressure Bracelet Could Combat Hypertension For those with blood pressure problems who hate blood pressure cuffs, hope is here. Swiss biotech aktiia has raised €3.6M to market a medical bracelet that could monitor your blood pressure 24/7. “Think of aktiia as the first medical device to measure blood pressure for long periods of time … that does not influence your […] September 25, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 25 Sep 2018 How to Overcome Failure as a Biotech Company Turning failure into success is a difficult but much needed skill in a high-risk industry such as biotech. At our latest Labiotech Refresh event, Christine Placet, now the CEO of ophthalmic gene therapy company Horama, shared her personal story of how she saved her previous company, Trophos, from an almost certain failure. The mission of […] September 25, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 24 Sep 2018 Gene Therapy Improves Eyesight of Patients With Inherited Blindness UK startup Nightstar Therapeutics has reported good safety and early signs of visual improvements in a Phase I/II trial with a gene therapy for a rare form of inherited blindness. One month after being treated with Nightstar’s gene therapy, five of the 18 patients enrolled in the trial have already shown improvements in their vision. […] September 24, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 22 Sep 2018 Art Made With Kombucha Explores the Science of the Microbiome Artist Alanna Lynch uses kombucha as an art medium to explore our relationship with the microbiome, which is now in the spotlight of human health. An ancient drink made of fermented tea, kombucha is now, over 2,000 years later, exploding in popularity. This week, Coca-Cola acquired an Australian kombucha company in an aim to enter […] September 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2018 RNA Therapy Shows Promise for Treating Liver Cancer British biotech MiNA Therapeutics’ innovative RNA treatment may enhance liver cancer patients’ response to standard cancer therapies, suggest early results from a Phase I/IIa clinical trial. When they received the biotech’s small activating RNA (saRNA) treatment, two patients showed complete responses after being given the cancer treatment sorafenib and one showed a partial response to […] September 20, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email